## Lawrence Engmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10270083/publications.pdf

Version: 2024-02-01

27 papers 1,150 citations

16 h-index 26 g-index

27 all docs

27 docs citations

times ranked

27

900 citing authors

#	Article	IF	CITATIONS
1	The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertility and Sterility. 2008, 89, 84-91.	0.5	392
2	Predictors of pregnancy and live-birth in couples with unexplained infertility after ovarian stimulation–intrauterine insemination. Fertility and Sterility, 2016, 105, 1575-1583.e2.	0.5	87
3	GnRH agonist trigger for the induction of oocyte maturation in GnRH antagonist IVF cycles: a SWOT analysis. Reproductive BioMedicine Online, 2016, 32, 274-285.	1.1	86
4	Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype. American Journal of Obstetrics and Gynecology, 2017, 216, 493.e1-493.e13.	0.7	78
5	The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Fertility and Sterility, 2008, 89, 554-561.	0.5	66
6	Luteal phase supplementation afterÂgonadotropin-releasing hormone agonist trigger in fresh embryo transfer: the American versus European approaches. Fertility and Sterility, 2015, 103, 879-885.	0.5	61
7	Impact of trophectoderm biopsy on obstetric and perinatal outcomes following frozen–thawed embryo transfer cycles. Human Reproduction, 2021, 36, 340-348.	0.4	46
8	A randomized trial of microdose leuprolide acetate protocol versus luteal phase ganirelix protocol in predicted poor responders. Fertility and Sterility, 2011, 95, 2531-2533.	0.5	41
9	Maternal and perinatal outcomes in programmed versus natural vitrified–warmed blastocyst transfer cycles. Reproductive BioMedicine Online, 2020, 41, 300-308.	1.1	41
10	Agonist trigger: what is the best approach? Agonist trigger with aggressive luteal support. Fertility and Sterility, 2012, 97, 531-533.	0.5	40
11	Pregnancy rates for single embryo transfer (SET) of day 5 and day 6 blastocysts after cryopreservation by vitrification and slow freeze. Journal of Assisted Reproduction and Genetics, 2017, 34, 913-919.	1.2	40
12	Frozen blastocyst transfer outcomes in immediate versus delayed subsequent cycles following GnRH agonist or hCG triggers. Journal of Assisted Reproduction and Genetics, 2018, 35, 669-675.	1.2	28
13	Euploidy rates between cyclesÂtriggered with gonadotropin-releasing hormoneÂagonist and human chorionic gonadotropin. Fertility and Sterility, 2019, 112, 258-265.	0.5	25
14	Ovarian Hyperstimulation Syndrome Prevention Strategies: Luteal Support Strategies to Optimize Pregnancy Success in Cycles with Gonadotropin-Releasing Hormone Agonist Ovulatory Trigger. Seminars in Reproductive Medicine, 2010, 28, 506-512.	0.5	23
15	The updated Cochrane review 2014 on GnRH agonist trigger: repeating the same errors. Reproductive BioMedicine Online, 2015, 30, 563-565.	1.1	20
16	Luteal phase support after gonadotropin-releasing hormone agonist triggering: does it still matter?. Fertility and Sterility, 2018, 109, 763-767.	0.5	18
17	In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger ofÂoocyte maturation. Fertility and Sterility, 2011, 96, 198-202.	0.5	11
18	Correlation of normal-range FMR1 repeat length or genotypes and reproductive parameters. Journal of Assisted Reproduction and Genetics, 2016, 33, 1149-1155.	1.2	9

#	Article	IF	Citations
19	Black race associated with lower live birth rate in frozen-thawed blastocyst transfer cycles: an analysis of 7,002 Society for Assisted Reproductive Technology frozen-thawed blastocyst transfer cycles. Fertility and Sterility, 2022, 117, 360-367.	0.5	8
20	Predictors of participant retention in infertility treatment trials. Fertility and Sterility, 2015, 104, 1236-1243.e2.	0.5	7
21	Pregnancy outcomes after frozen-thawed single euploid blastocyst transfer following IVF cycles using GNRH agonist or HCG trigger for final oocyte maturation. Journal of Assisted Reproduction and Genetics, 2020, 37, 611-617.	1.2	6
22	Independent serum markers of corpora lutea function after gonadotropin-releasing hormone agonist trigger and adjuvant low dose human chorionic gonadotropin in inÂvitro fertilization. Fertility and Sterility, 2019, 112, 534-544.	0.5	5
23	The dual trigger study: Rationale and study design of a prospective double-blind randomized clinical trial comparing pregnancy rates after co-administration of low dose hCG at the time of GnRH agonist trigger or 35Ah later for the prevention of OHSS. Contemporary Clinical Trials Communications, 2017, 8, 18-24.	0.5	4
24	Embryologic outcomes among patients using a microfluidics chip compared to density gradient centrifugation to process sperm: a paired analysis. Journal of Assisted Reproduction and Genetics, 2022, 39, 1523-1529.	1.2	4
25	Reduction in multiple pregnancy rate in donor oocyte–recipient gestational carrier (GC) in vitro fertilization (IVF) cycles in the USA with single-embryo transfer and preimplantation genetic testing. Journal of Assisted Reproduction and Genetics, 2021, 38, 1441-1447.	1.2	3
26	Factors associated with study protocol adherence and bio banking participation in reproductive medicine clinical trials and their relationship to live birth. Human Reproduction, 2020, 35, 2819-2831.	0.4	1
27	Occult abnormal pregnancies after first post–embryo transfer serum beta-human chorionic gonadotropin levels of 1.0–5.0 mlU/mL. Fertility and Sterility, 2016, 105, 938-945.e1.	0.5	O